Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies
Business Wire India
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL
Sonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in…